Trials / Completed
CompletedNCT00911144
Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
Booster Vaccination With Pneumococcal Vaccine GSK1024850A or Prevenar™ Co-administered With Hiberix™ in Children Primed With the Same Vaccines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of a booster (fourth) dose of pneumococcal vaccine GSK1024850A when co-administered with Hiberix at 12-18 months of age, in children primed with the same vaccines in primary study NCT00680914.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A) | Intramuscular injection, administered as a single dose |
| BIOLOGICAL | Wyeth-Lederle's Prevenar™ | Intramuscular injection, administered as a single dose |
| BIOLOGICAL | GSK Biologicals' Hiberix™ | Intramuscular injection, administered as a single dose |
Timeline
- Start date
- 2009-06-11
- Primary completion
- 2010-01-11
- Completion
- 2010-01-11
- First posted
- 2009-06-01
- Last updated
- 2018-09-20
- Results posted
- 2011-01-19
Locations
14 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00911144. Inclusion in this directory is not an endorsement.